Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170721 | 0.85 | CYP2C9 (0.33) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL24985319 | 0.85 | PDE2A (0.40) | PTGS2PDE2ALMNAGABRA1GABRB1 | |
| SCHEMBL22768024 | 0.82 | EIF4A3 (0.34) | PDE2ASMN1; SMN2 | |
| SCHEMBL21901895 | 0.80 | TP53 (0.31) | TP53CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL8295701 | 0.79 | GABRA1 (0.39) | PTGS2PDE2ATP53SMN1; SMN2LMNA | |
| SCHEMBL15701548 | 0.79 | SMN1; SMN2 (0.38) | PTGS2TP53CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL13699139 | 0.78 | EIF4A3 (0.34) | PDE2ASMN1; SMN2 | |
| SCHEMBL18350805 | 0.77 | LMNA (0.42) | PTGS2PDE2ATP53LMNAGABRA1 | |
| SCHEMBL17083896 | 0.77 | SMN1; SMN2 (0.37) | PTGS2TP53CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12309968 | 0.77 | GABRA1 (0.38) | PTGS2PDE2ATP53CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | PTGS2 1278/4885PDE2A 224/4885TP53 1257/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | PTGS2 1278/4885PDE2A 224/4885TP53 1257/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | PTGS2 1278/4885PDE2A 224/4885TP53 1257/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | PTGS2 1369/4885PDE2A 304/4885TP53 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.